Core Insights - Polyrizon Ltd. has submitted a full pre-submission package to the FDA for its PL-14 product aimed at treating nasal allergies, marking a significant step in its regulatory strategy [1][3] - The PL-14 Allergy Blocker is a non-invasive nasal spray that creates a physical barrier to provide rapid and long-lasting relief from allergic rhinitis symptoms [2][3] - The CEO of Polyrizon emphasized the potential of PL-14 to transform treatment options for the hundreds of millions affected by allergic rhinitis globally [3] Company Overview - Polyrizon is a biotechnology company focused on developing innovative medical device hydrogels delivered as nasal sprays, which act as a barrier against viruses and allergens [3] - The company utilizes proprietary Capture and Contain TM hydrogel technology, which consists of naturally occurring building blocks, to create a protective shield in the nasal cavity [3] - Polyrizon is also developing additional technologies for nasal delivery of active pharmaceutical ingredients, referred to as Trap and Target ™ [3]